Role of the ubiquitin-like modifier FAT10 in protein degradation and ...

More documents

Recommendations

Info

Record of Contributions Chapter 1: The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10 I performed the experiments depicted in figures 6, 13G and 13H and helped write the paper. This chapter was published in J. Biol. Chem. 281(29): 20045-54. 2006. Chapter 2: Degradation of FAT10 by the 26S proteasome in vitro is inde- pendent of ubiquitylation but relies on NUB1L I established the in vitro degradation assay and wrote the paper. This chapter was submitted for publication. Chapter 3: The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition I designed and performed all of the experiments in this chapter and wrote the paper. This chapter was published in J. Cell Sci. 121(24): 4079-4088. 2008. Chapter 4: FAT10-deficient mice display a prolonged CD8 + T-cell response after LCMV infection I performed the genotyping and supervised the breeding of FAT10 -/- mice. In ad- dition, I performed the experiments investigating the maturation-induced apoptosis of BMDCs as well as preliminary experiments investigating the CD8 + T cell response to LCMV. Chapter 5: Generation of mouse monoclonal antibodies directed against human FAT10 I generated the antibodies and performed the experiments depicted in all figures except for figure 32. 145
Page 1 and 2:
Role of the ubiquitin-like modifier
Page 3 and 4:
Acknowledgements . . . . . . . . .
Page 5 and 6:
Summary / Zusammenfassung English F
Page 7 and 8:
Summary In conclusion, these result
Page 9 and 10:
Summary nicht von der katalytischen
Page 11 and 12:
The Ubiquitin-Proteasome-System The
Page 13 and 14:
Introduction Figure 1: The 26S prot
Page 15 and 16:
Introduction are the major source o
Page 17 and 18:
Introduction majority of ubiquitin-
Page 19 and 20:
Introduction example contained in t
Page 21 and 22:
Introduction two modifiers apart fr
Page 23 and 24:
Introduction Figure 4: Comparison o
Page 25 and 26:
Introduction dependent apoptosis in
Page 27 and 28:
Introduction Interestingly, a recen
Page 29 and 30:
The Autophagy-Lysosome System Intro
Page 31 and 32:
Introduction Figure 5: Molecular ma
Page 33 and 34:
Introduction The transport of misfo
Page 35 and 36:
Introduction where the proteasome i
Page 37 and 38:
Chapter 1 The UBA domains of NUB1L
Page 39 and 40:
Introduction Chapter 1 Ubiquitin, a
Page 41 and 42:
Chapter 1 no correlation between th
Page 43 and 44:
Chapter 1 covered proteins were sep
Page 45 and 46:
Chapter 1 Figure 8: Accelerated deg
Page 47 and 48:
Chapter 1 Treatment with IFN-γ and
Page 49 and 50:
Chapter 1 ing SUMO-1-GFP or the C-t
Page 51 and 52:
Chapter 1 Figure 12: Accelerated de
Page 53 and 54:
Chapter 1 Figure 13: Co-immunopreci
Page 55 and 56:
Chapter 1 domains of NUB1L is requi
Page 57 and 58:
Chapter 1 Rad23 (Verma et al., 2004
Page 59 and 60:
Chapter 1 FAT10-GFP expressing vect
Page 61 and 62:
Chapter 2 Degradation of FAT10 by t
Page 63 and 64:
Introduction Chapter 2 The proteaso
Page 65 and 66:
Chapter 2 From our previous data it
Page 67 and 68:
Chapter 2 Figure 14: Purified compo
Page 69 and 70:
Chapter 2 evaluation of the NUB1L b
Page 71 and 72:
Chapter 2 teins which contain intri
Page 73 and 74:
Chapter 2 Combined with our studies
Page 75 and 76:
Chapter 2 Recombinant expression of
Page 77 and 78:
Chapter 2 et al., 2003), both at a
Page 79 and 80:
Abstract Chapter 3 During misfolded
Page 81 and 82:
Chapter 3 tion between the UPS and
Page 83 and 84:
Chapter 3 Figure 18: HDAC6 interact
Page 85 and 86:
Chapter 3 Figure 19: Both the BUZ d
Page 87 and 88:
Chapter 3 of HDAC6 was required for
Page 89 and 90:
Chapter 3 precipitates with HDAC6 (
Page 91 and 92:
90 Chapter 3
Page 93 and 94:
Chapter 3 Figure 23: The model conj
Page 95 and 96: Chapter 3 HDAC6 is required for the
Page 97 and 98: Chapter 3 Figure 26: Both ubiquitin
Page 99 and 100: Chapter 3 also revealed endogenous,
Page 101 and 102: Chapter 3 and/or its conjugates is
Page 103 and 104: Chapter 3 (Hipp et al., 2005), pEGF
Page 105 and 106: Chapter 4 FAT10-deficient mice disp
Page 107 and 108: Chapter 4 Once the infection is cle
Page 109 and 110: Chapter 4 As both wild-type as well
Page 111 and 112: Chapter 4 Peptides. The synthetic p
Page 113 and 114: Introduction Chapter 5 Antibodies a
Page 115 and 116: Chapter 5 binant human and mouse GS
Page 117 and 118: Chapter 5 Figure 34: The antibodies
Page 119 and 120: Chapter 5 Figure 36: The antibody s
Page 121 and 122: Discussion 30 years ago, ubiquitin
Page 123 and 124: Discussion monomeric ubiquitin as w
Page 125 and 126: Discussion Alternatively, FAT10 cou
Page 127 and 128: References D. T. Akey, X. Zhu, M. D
Page 129 and 130: References Y.-H. Chiu, Q. Sun, and
Page 131 and 132: References S. Gunawardena, L.-S. He
Page 133 and 134: References J. A. Johnston, M. E. Il
Page 135 and 136: References F. Lévy, N. Johnsson, T
Page 137 and 138: References J.-H. Park, H.-S. Jong,
Page 139 and 140: References P. Schreiner, X. Chen, K
Page 141 and 142: References S. Vijay-Kumar, C. E. Bu
Page 143 and 144: Abbreviations aa amino acid AAA ATP
Page 145: Amino Acids Alanine Ala A Arginine
show all

Role of the ubiquitin-like modifier FAT10 in protein degradation and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?